Peroxiredoxin 6 suppresses Muc5ac overproduction in LPS-induced airway inflammation through H 2 O 2 -EGFR-MAPK signaling pathway.

•Excessive mucin production are the common mechanism and characteristics of chronic obstructive pulmonary disease (COPD) and bronchial asthma.•We demonstrate that Peroxiredoxin 6 (Prdx6) plays important roles in the development of mucin overproduction after LPS exposure.•Treatment with Prdx6 may provide a new therapy against airway inflammation in the future.